ACO Information - Collaborative Care of Florida - Accountable Care Organization

ACO Name and Location

Collaborative Care of Florida LLC
1414 Kuhl Ave. MP2
Orlando, Florida 32806 

ACO Primary Contact

Primary Contact Name

Robyn Bartek

Primary Contact Phone Number

321.842.8366

Primary Contact Email Address

[email protected]

Organizational Information

ACO participants:

ACO Participants

ACO Participant in Joint Venture (Enter Y or N)

West Orange Physicians Group, LLC

N

Orlando Health, Inc.

N

Orlando Physicians Network, Inc

N

Physician Associates, LLC

N

ACO governing body:

Member

Member's Voting Power

Membership Type

ACO Participant TIN Legal Business Name/DBA, if Applicable

Last Name

First Name

Title/Position

Senne

Jerry

Executive Director

1

ACO Participant Representative

Orlando Health

Spong

Bernadette

Chief Financial Officier, Orlando Health

1

ACO Participant Representative

Orlando Health

Pattee

Curt

Chief Financial Officier, Orlando Health Physician Group

1

ACO Participant Representative

Orlando Health

Walker

Erik

MD

1

ACO Participant Representative

Orlando Health Physician Associates

Kaplan

Benjamin

MD

1

ACO Participant Representative

Orlando Physicians Network

Jackson

Amy

MD

1

ACO Participant Representative

West Orange Physician Group

Desai

Sunil

MD

1

ACO Participant Representative

Orlando Health

Soto

Martin

MD

1

ACO Participant Representative

Orlando Health Physician Associates

MacDiarmid

Malcolm

 

1

Medicare Beneficiary Representative

 

Key ACO clinical and administrative leadership:

Jerry Senne

ACO Executive

Martin Soto

Medical Director

Dave Huddleson

Compliance Officer

Benjamin Kaplan

Quality Assurance/Improvement Officer

Associated committees and committee leadership:

Committee Name

Committee Leader Name and Position

Quality Improvement and Care Coordination

Benjamin Kaplan, MD, Chair

Finance and Operations

Erik Walker, MD, Chair

Compliance

David Huddleson, Chair

 

  

Types of ACO participants, or combinations of participants, that formed the ACO:

  • ACO professionals in a group practice arrangement
  • Partnerships or joint venture arrangements between hospitals and ACO professionals
  • Hospital employing ACO professionals

Shared Savings and Losses

Amount of Shared Savings/Losses

  • Second Agreement Period
    • Performance Year 2016, $0
  • First Agreement Period
    • Performance Year 2015, $2,696,226
    • Performance Year 2014, $2,421,969
    • Performance Year 2013, $1,469,180 

Shared Savings Distribution

  • Second Agreement Period
    • Performance Year 2016
      • Proportion invested in infrastructure: N/A
      • Proportion invested in redesigned care processes/resources: N/A
      • Proportion of distribution to ACO participants: N/A
  • First Agreement Period
    • Performance Year 2015
      • Proportion invested in infrastructure: 20%
      • Proportion invested in redesigned care processes/resources: 40%
      • Proportion of distribution to ACO participants: 40%
    • Performance Year 2014
      • Proportion invested in infrastructure: 20%
      • Proportion invested in redesigned care processes/resources: 40%
      • Proportion of distribution to ACO participants: 40%
    • Performance Year 2013
      • Proportion invested in infrastructure: 20%
      • Proportion invested in redesigned care processes/resources: 40%
      • Proportion of distribution to ACO participants: 40% 

Quality Performance Results

2016 Quality Performance Results:

ACO#

Measure Name

Rate

ACO Mean

ACO-1

CAHPS: Getting Timely Care, Appointments, and Information

80.87

80.51

ACO-2

CAHPS: How Well Your Providers Communicate

93.40

93.01

ACO-3

CAHPS: Patients’ Rating of Provider

93.14

92.25

ACO-4

CAHPS: Access to Specialists

86.54

83.49

ACO-5

CAHPS: Health Promotion and Education

64.71

60.32

ACO-6

CAHPS: Shared Decision Making

75.71

75.40

ACO-7

CAHPS: Health Status/Functional Status

73.69

72.30

ACO-34

CAHPS: Stewardship of Patient Resources

28.21

26.97

ACO-8

Risk Standardized, All Condition Readmission

14.48

14.70

ACO-35

Skilled Nursing Facility 30-day All-Cause Readmission measure (SNFRM)

18.58

18.17

ACO-36

All-Cause Unplanned Admissions for Patients with Diabetes

41.77

53.20

ACO-37

All-Cause Unplanned Admissions for Patients with Heart Failure

61.90

75.23

ACO-38

All-Cause Unplanned Admissions for Patients with Multiple Chronic Conditions

46.60

59.81

ACO-9

Ambulatory Sensitive Condition Admissions: Chronic Obstructive Pulmonary Disease or Asthma in Older Adults (AHRQ Prevention Quality Indicator (PQI) #5)

10.69

9.27

ACO-10

Ambulatory Sensitive Conditions Admissions: Heart Failure (AHRQ Prevention Quality Indicator (PQI) #8)

13.47

14.53

ACO-11

Percent of PCPs who Successfully Meet Meaningful Use Requirements

98.59

82.72

ACO-39

Documentation of Current Medications in the Medical Record

94.86

87.54

ACO-13

Falls: Screening for Future Fall Risk

84.45

64.04

ACO-14

Preventive Care and Screening: Influenza Immunization

85.63

68.32

ACO-15

Pneumonia Vaccination Status for Older Adults

91.33

69.21

ACO-16

Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up

92.24

74.45

ACO-17

Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention

99.34

90.98

ACO-18

Preventive Care and Screening: Screening for Clinical Depression and Follow-up Plan

73.72

53.63

ACO-19

Colorectal Cancer Screening

71.66

61.52

ACO-20

Breast Cancer Screening

75.08

67.61

ACO-21

Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented

86.09

76.79

ACO-42

Statin therapy for the Prevention and Treatment of Cardiovascular Disease

84.48

77.72

ACO-27

Diabetes Mellitus: Hemoglobin A1c Poor Control

9.9

18.24

ACO-41

Diabetes: Eye Exam

42.49

44.94

ACO-28

Hypertension (HTN): Controlling High Blood Pressure

77.23

70.69

ACO-30

Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic

84.70

85.05

ACO-31

Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)

89.12

88.67

ACO-33

Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy - for patients with CAD and Diabetes or Left Ventricular Systolic Dysfunction (LVEF<40%)

91.11

79.67

Please note, the ACO-40 Depression Remission at 12 months quality measure is not included in public reporting due to low samples.

Note: In the Quality Performance Results file(s) above, search for “Collaborative Care of Florida LLC” to view the quality performance results. This ACO can also be found by using the ACO ID A94621 in the public use files on data.cms.gov.

Payment Rule Waivers

  • No, our ACO does not use the SNF 3-Day Rule Waiver.